Literature DB >> 32563658

Comparison Between ESC and Duke Criteria for the Diagnosis of Prosthetic Valve Infective Endocarditis.

Mary Philip1, Laetitia Tessonier2, Julien Mancini3, Jean-Luc Mainardi4, Marie-Paule Fernandez-Gerlinger4, David Lussato5, David Attias5, Serge Cammilleri2, Pierre Weinmann6, Albert Hagege7, Florent Arregle1, Hélène Martel1, Leopold Oliver1, Laurence Camoin8, Anne Claire Casalta1, Jean Paul Casalta8, Frédérique Gouriet8, Alberto Riberi9, Hubert Lepidi8, Didier Raoult8, Michel Drancourt8, Gilbert Habib10.   

Abstract

OBJECTIVES: The primary objective was to assess the value of the European Society of Cardiology (ESC) criteria, including 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) in prosthetic valve infective endocarditis (PVE). Secondary objectives were: 1) to assess the reproducibility of 18F-FDG-PET/CT; 2) to compare its diagnostic value with that of echocardiography; and 3) to assess the diagnostic value of the presence of a diffuse splenic uptake
BACKGROUND: 18F-FDG PET/CT has been added as a major criterion in the ESC 2015 infective endocarditis (IE) guidelines, but the benefit of the ESC criteria has not been prospectively compared with the conventional Duke criteria.
METHODS: Between 2014 and 2017, 175 patients with suspected PVE were prospectively included in 3 French centers. After exclusion of patients with uninterpretable 18F-FDG PET/CT, 115 patients were evaluated, including 91 definite and 24 rejected IE, as defined by an expert consensus.
RESULTS: Cardiac uptake by 18F-FDG PET/CT was observed in 67 of 91 patients with definite PVE and 6 with rejected IE (sensitivity 73.6% [95% confidence interval (CI): 63.3% to 82.3%], specificity 75% [95% CI: 53.3% to 90.2%]). The ESC 2015 classification increased the sensitivity of Duke criteria from 57.1% (95% CI: 46.3% to 67.5%) to 83.5% (95% CI: 74.3% to 90.5%) (p < 0.001), but decreased its specificity from 95.8% (95% CI: 78.9% to 99.9%) to 70.8% (95% CI: 48.9% to 87.4%). Intraobserver reproducibility of 18F-FDG PET/CT was good (kappa = 0.84) but interobserver reproducibility was less satisfactory (kappa = 0.63). A diffuse splenic uptake was observed in 24 (20.3%) patients, including 23 (25.3%) of definite PVE, and only 1 (4.2%) rejected PVE (p = 0.024).
CONCLUSIONS: 18F-FDG PET/CT is a useful diagnostic tool in suspected PVE, and explains the greater sensitivity of ESC criteria than Duke criteria. However, 18F-FDG PET/CT also presents with important limitations concerning its feasibility, specificity, and reproducibility. Our study describes for the first time a new endocarditis criterion, that is, the presence of a diffuse splenic uptake on 18F-FDG PET/CT.
Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  endocarditis; guidelines; nuclear imaging; valve disease

Year:  2020        PMID: 32563658     DOI: 10.1016/j.jcmg.2020.04.011

Source DB:  PubMed          Journal:  JACC Cardiovasc Imaging        ISSN: 1876-7591


  4 in total

Review 1.  Staphylococcus Aureus Infective Endocarditis: JACC Patient Pathways.

Authors:  Julia Grapsa; Christopher Blauth; Y S Chandrashekhar; Bernard Prendergast; Blair Erb; Michael Mack; Valentin Fuster
Journal:  JACC Case Rep       Date:  2021-11-15

2.  18F-FDG PET/CT: Not only a promise for complex scenarios-let's talk about aortic grafts.

Authors:  Albert Roque; María Nazarena Pizzi
Journal:  J Nucl Cardiol       Date:  2021-12-21       Impact factor: 5.952

3.  Advantages of 18F-FDG PET/CT Imaging over Modified Duke Criteria and Clinical Presumption in Patients with Challenging Suspicion of Infective Endocarditis.

Authors:  Valentin Pretet; Cyrille Blondet; Yvon Ruch; Matias Martinez; Soraya El Ghannudi; Olivier Morel; Yves Hansmann; Thomas H Schindler; Alessio Imperiale
Journal:  Diagnostics (Basel)       Date:  2021-04-18

Review 4.  Nuclear Imaging in Infective Endocarditis.

Authors:  Nidaa Mikail; Fabien Hyafil
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.